ADHD Biotypes and Personalized Medication
Author Information
Author(s): Feng Aichen, Zhi Dongmei, Feng Yuan, Jiang Rongtao, Fu Zening, Xu Ming, Zhao Min, Yu Shan, Stevens Michael, Sun Li, Calhoun Vince, Sui Jing
Primary Institution: Peking University Sixth Hospital
Hypothesis
Identifying neuroimaging markers for ADHD biotypes can lead to more personalized treatment approaches.
Conclusion
The study identified two ADHD biotypes that differ in cognitive performance and treatment response, suggesting a potential for personalized medication strategies.
Supporting Evidence
- Two ADHD biotypes were identified with significant differences in cognitive abilities.
- Biotype 1 showed better recovery rates when treated with methylphenidate compared to atomoxetine.
- Functional connectivity patterns were consistent across two independent datasets.
Takeaway
There are different types of ADHD, and knowing which type someone has can help doctors choose the best medicine for them.
Methodology
The study used a graph convolution network to analyze functional imaging and phenotypic data from ADHD patients to identify biotypes.
Potential Biases
Potential biases may arise from the selection of participants and the reliance on self-reported measures.
Limitations
The study's findings may not be generalizable due to differences in the datasets used and the limited number of patients receiving medication.
Participant Demographics
Participants included 1069 ADHD patients from the ABCD study and 130 ADHD patients from Peking University, aged 9-15.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website